GlassScriptPhysician profile
Troy W Trayer
NPI 1689842049
$3,738.26
in general payments reported to CMS, 2019-2025
27 companies · $162 in 2025
The $162 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,389 · 2020: $564 · 2021: $490 · 2022: $590 · 2023: $394 · 2024: $150 · 2025: $162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $706.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $705.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $956.16 | 2019-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Pfizer INC. | $292.88 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $278.89 | 2019-2025 | Lifevest |
| Boston Scientific Corporation | $187.12 | 2019-2024 | Angiojet Ultra 5000a, Lux-Dx Insertable Cardiac Monitor |
| Janssen Pharmaceuticals, INC | $179.84 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $172.98 | 2019-2024 | Camzyos, Eliquis |
| Medtronic, INC. | $171.84 | 2021-2022 | |
| Amgen INC. | $164.03 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $144.60 | 2022 | |
| Amarin Pharma, INC. | $125.57 | 2019-2022 | |
| Genzyme Corporation | $125.00 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2021 | |
| Medtronic Vascular, INC. | $119.20 | 2019 | |
| Cordis US Corp. | $101.48 | 2023-2025 | Brite Tip Radianz, Mynx Control Venous, Precise Pro Rx |
| Avinger INC. | $87.44 | 2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.69 | 2019 | |
| Abbott Laboratories | $59.28 | 2020-2024 | Ultreon, Diamondback Peripheral |
| Novartis Pharmaceuticals Corporation | $56.81 | 2019-2022 | |
| Cook Medical LLC | $55.90 | 2019 | |
| Cardinal Health 200 LLC | $55.44 | 2019-2020 | |
| Abiomed | $49.68 | 2020-2023 | Impella |
| Shockwave Medical, INC | $47.41 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $38.47 | 2019 | |
| Sanofi-Aventis U.S. LLC | $24.16 | 2023 | |
| Chiesi USA, INC. | $20.33 | 2020 | |
| Merck Sharp & Dohme LLC | $16.34 | 2022 | |
| W. L. Gore & Associates, INC. | $15.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Troy Trayer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.